EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study

Nikolaos Fountoulakis, Panagiotis Pavlou, Luigi Gnudi, Giuseppe Maltese, Angeliki Panagiotou, Salma Ayis, Fowzia Ibrahim, Janaka Karalliedde

Frontiers in Endocrinology · 2026

DOI: 10.3389/fendo.2026.1908356 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Endocrinology, 2026. Verfasst von Nikolaos Fountoulakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Albuminuria, Cholagogues and Choleretics, Diabetes Mellitus, Type 1, Diabetic Nephropathies. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research for Patient Benefit Programme, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In animal models of diabetic kidney disease (DKD), ursodeoxycholic acid (UDCA) reduces albuminuria and improves histological changes associated with DKD. The purpose of this study was to investigate the potential renoprotective role of UDCA in people with type 1 diabetes (T1D) and DKD.

Methods

In this single-centre, double-blind, placebo-controlled crossover trial, participants with T1D and DKD with residual albuminuria (urine albumin to creatinine ratio, > 3 mg/mmol) on a maximum tolerated, stable dose of renin–angiotensin system (RAS) blockade with estimated glomerular filtration rate (eGFR) ≥ 30 ml/min were included. Participants were randomly allocated to UDCA (500 mg BID) or placebo for 24 weeks, with a 4-week washout period in between. The primary endpoint was the change in urine albumin excretion rate (UAER), measured from timed urine collections after 24 weeks of treatment with UDCA compared with placebo.

Results

Thirty-one participants were included, of whom 21 were men; the median age (interquartile range [IQR]) was 54.2 (22.7–75.3) years. The baseline median (IQR) UAER was 26 (12.3–189.0) μg/min for UDCA and 32.1 (19.9–88.2) μg/min for placebo. The median (IQR) posttreatment UAER was 36.2 (14.9–174.0) μg/min for UDCA and 38.5 (17.6–194.0) μg/min for placebo, with no significant difference in UAER between treatments ( p -value = 0.4).

Conclusion

In this first-ever human study investigating the potential renoprotective effect of UDCA treatment for 24 weeks in people with T1D and DKD, we did not observe a significant reduction in UAER. Further studies are required to evaluate the role of UDCA in DKD. Clinical trial registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003609-41 , identifier 2015-003609-41.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminuriaCholagogues and CholereticsDiabetes Mellitus, Type 1Diabetic NephropathiesUrsodeoxycholic AcidAdultAgedFemaleHumansMaleMiddle AgedYoung AdultCross-Over StudiesDouble-Blind MethodGlomerular Filtration RateProof of Concept Study

Stichwörter der Autor:innen

albuminuriaclinical trialdiabetic kidney diseasetype 1 diabetesursodeoxycholic acid

Substanzen

Cholagogues and CholereticsUrsodeoxycholic Acid

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, United Kingdom.
  • School of Life Course and Population Sciences, King's College London, London, United Kingdom.
  • King's College London, British Heart Foundation Centre of Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, United Kingdom.

Förderung

  • Research for Patient Benefit Programme
  • British Heart Foundation

Zitieren

APA

Fountoulakis, N., Pavlou, P., Gnudi, L., Maltese, G., Panagiotou, A., Ayis, S., Ibrahim, F., & Karalliedde, J. (2026). The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1908356

Vancouver

Fountoulakis N, Pavlou P, Gnudi L, Maltese G, Panagiotou A, Ayis S, et al. The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1908356

BibTeX
@article{Fountoulakis2026,
  author = {Fountoulakis, Nikolaos and Pavlou, Panagiotis and Gnudi, Luigi and Maltese, Giuseppe and Panagiotou, Angeliki and Ayis, Salma and Ibrahim, Fowzia and Karalliedde, Janaka},
  title = {The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  doi = {10.3389/fendo.2026.1908356}
}
Kostenlos starten →